CD4 and neoplasm: Overall, our study demonstrates the efficacy of ACT with NeoAg-specific CD4+ T cells in a physiologically relevant tumor model and brings new insights to the use of similar approaches for adoptive immunotherapy of human cancer to empower more diverse, potent and durable antitumor immune responses.